Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix Q2 10-Q Reveals Material Weakness and $59M Letter of Credit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.65
Mkt Cap
$557.008M
52W Low
$6.125
52W High
$14.96
52W Position info
25% above low
Off High info
49% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CRMD sits 25% above its 52-week low of $6.125.

Summary

CorMedix filed its Q2 10-Q, confirming strong revenue growth but disclosing an unremediated material weakness, a $59M letter of credit arrangement, and an impairment indicator for oritavancin products.


Key Events · Earnings and Guidance · CRMD

  • Material Weakness Unremediated

    Management concluded disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness in internal control over financial reporting related to review of significant non-routine transactions. The weakness remains unremediated.

  • $59M Letter of Credit

    Subsequent to quarter end, CorMedix agreed to defer volume-based rebate payments to a customer and will issue a letter of credit for approximately $59 million, requiring an equal amount of cash to be held as restricted collateral.

  • Oritavancin Impairment Indicator

    The company identified an impairment indicator for KIMYRSA and ORBACTIV during Q2. No impairment was recorded as of June 30, 2026, but management notes a material impairment charge is reasonably possible in a future period.

  • Strong Q2 Financials

    Q2 revenue was $101.9 million, up 157% year-over-year, with net income of $26.0 million. Cash and equivalents totaled $256.7 million at quarter end.


Analysis · CRMD · Life Sciences

CorMedix's 10-Q confirms strong Q2 results but adds three material items not in the 8-K: an unremediated material weakness in internal controls, a subsequent event requiring a $59 million letter of credit with restricted cash, and an impairment indicator for its oritavancin products. The material weakness signals ongoing financial reporting risk, while the letter of credit ties up a significant portion of cash and reflects customer payment pressure. The impairment indicator raises the possibility of a future write-down. These disclosures add downside risk to an otherwise positive earnings report.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRMD was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557M. The 52-week trading range was $6.13 to $14.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 16, 2026, 7:30 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $4.61
Real-time Price: $4.54 info
Change: -$0.075 (-2%) info
Market Cap: $359.112M info
CRMD
Nov 12, 2026, 8:21 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $4.54 info
Change: -$0.615 (-12%) info
Market Cap: $359.112M info
CRMD
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.54 info
Change: -$0.715 (-14%) info
Market Cap: $359.112M info
CRMD
Nov 12, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.54 info
Change: -$0.715 (-14%) info
Market Cap: $359.112M info
CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $4.54 info
Change: -$0.965 (-18%) info
Market Cap: $359.112M info